Get the Stockscreener App
8.40
2.44%
0.20
Aura Biosciences Inc stock is traded at $8.40, with a volume of 1.04M.
It is up +2.44% in the last 24 hours and up +24.08% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$8.20
Open:
$8.15
24h Volume:
1.04M
Relative Volume:
2.59
Market Cap:
$926.52M
Revenue:
-
Net Income/Loss:
$-106.19M
P/E Ratio:
-4.6352
EPS:
-1.8122
Net Cash Flow:
$-85.19M
1W Performance:
+19.83%
1M Performance:
+24.08%
6M Performance:
+57.01%
1Y Performance:
+44.83%
1-Day Range:
$8.06
$8.46
1-Week Range:
$6.94
$9.535
52-Week Range:
$4.345
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
8.40 | 926.52M | 0 | -106.19M | -85.19M | -1.8122 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Resumed | Evercore ISI | Outperform |
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
View All
Aura Biosciences Inc Stock (AURA) Latest News
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Aura Biosciences (AURA) Eps Diluted (TTM) - Zacks Investment Research
Are medical stocks lagging Aura Biosciences (AURA) this year? - MSN
Aura Biosciences, Inc. Common Stock (AURA) Stock Price Today & Analysis - Gotrade
Aura Biosciences (AURA) insider Natalie Holles files initial Form 3 - Stock Titan
Norwegian Cruise Line, Aura Biosciences and other big stocks moving lower in Monday's pre-market session - MSN
Is Aura Bio (AURA) a value trap or a value play? (Momentum Fading) 2026-05-06Social Buzz Stocks - newser.com
Aura Biosciences closes $299.4 million public offering - Investing.com UK
Aura Biosciences prices $260M stock, warrant offering - MSN
Aura Biosciences Announces $39.6 Million Public Offering of Common Stock and Pre-Funded Warrants – Underwriting Agreement with Leerink Partners, TD Securities, and Evercore Group - Minichart
Aura Biosciences Completes Major Underwritten Equity Financing - TipRanks
Aura Biosciences closes $299.4 million public offering By Investing.com - Investing.com Australia
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Aura Biosciences Prices Equity Offering, Nets $280.8 Million; Underwritten by Leerink, TD, Evercore - TradingView
Aura Biosciences (NASDAQ: AURA) boosts cash runway with $280.8M raise and buyback - Stock Titan
Aura Biosciences Closes $299.4 Million Public Offering to Advance Precision Therapies for Solid Tumors - Quiver Quantitative
Aura raises $299M as underwriters take full extra-share option - Stock Titan
Aura Biosciences (NASDAQ: AURA) offers 39.6M shares, repurchase $39M - Stock Titan
AURA Stock Price, Quote & Chart | AURA BIOSCIENCES INC (NASDAQ:AURA) - ChartMill
Aura Biosciences Announces Stock Repurchase Agreement with Shareholder - TipRanks
Aura Biosciences (NASDAQ: AURA) plans 6.9M-share Matrix buyback - Stock Titan
Aura Biosciences prices $260.3M stock offering at $6/share By Investing.com - Investing.com Australia
Aura Biosciences launches public offering of common stock By Investing.com - Investing.com India
Aura Biosciences Appoints New CEO as Phase 3 CoMpass Trial for Belzupacap Sarotalocan Nears Enrollment Completion - Minichart
Aura Biosciences names Natalie Holles as new CEO By Investing.com - Investing.com South Africa
Aura Biosciences names Natalie Holles as new CEO - Investing.com UK
Aura Biosciences launches public offering of common stock - Investing.com UK
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big - Benzinga
Aura Biosciences prices $260.3M stock offering at $6/share - Investing.com
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants - The Manila Times
Aura Biosciences announces pricing of $260 million public offering of common stock and pre-funded warrants - marketscreener.com
Aura Biosciences Inc. Announces Pricing of $260.3 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Aura raises $260.3M, earmarks part to buy out Matrix stake - Stock Titan
Aura Biosciences Announces Pricing Of $260 Million Public Offering Of Common Stock And Pre-Funded Warrants - TradingView
Orion Corporation: Managers’ transactions – Kari Jussi Aho - Weekly Voice
Aura Biosciences Appoints Natalie Holles CEO as Phase 3 Trial Nears Enrollment Completion - citybiz
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Aura Biosciences (AURA) offers stock and pre-funded warrants; plans possible Matrix buyback - Stock Titan
Aura Biosciences Names Natalie Holles as CEO, Plans Public Offering - marketscreener.com
Aura Biosciences Advances CoMpass Phase 3 Trial Progress - TipRanks
New Aura Biosciences (NASDAQ: AURA) CEO as Phase 3 CoMpass trial nears enrollment - Stock Titan
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aura Biosciences Inc Stock (AURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kilroy Conor | See Remarks |
Apr 16 '26 |
Sale |
7.02 |
11,738 |
82,401 |
217,835 |
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):